Aug 06, 2026 —
Remedium Bio announced the initial close of a planned $10 million Series A financing to advance its platform for durable, adjustable gene therapies designed for chronic disease treatment.
The financing was led by Lifespan Vision Ventures, with participation from Eli Lilly and Company and HKX Capital. Harry Robb of Lifespan Vision Ventures has joined Remedium’s board. The company said it expects to complete the round with additional investors before the final close.
Remedium is developing the Prometheus™ platform, a proprietary dose-adjustable gene therapy technology designed to turn adipocytes, or fat cells, at the site of a minimally invasive subcutaneous injection into long-term producers of therapeutic proteins.
The approach is intended to replace repeated administration of protein or peptide medicines with a single genetic intervention that enables the patient’s own cells to produce therapeutic proteins over extended periods. A key feature of the platform is post-treatment dose adjustment, allowing therapeutic protein expression to be modified according to patient need.
Remedium is initially focused on large chronic disease areas across endocrinology, immunology, neurology, and musculoskeletal disease. The company has highlighted potential applications in type 2 diabetes, obesity, osteoarthritis, and stroke.
The platform is designed to localize treatment to adipocytes at the injection site, potentially reducing systemic vector exposure while using an accessible and biologically active tissue for therapeutic protein production. This localized strategy may help address some challenges associated with systemic gene therapy delivery, including tissue tropism, toxicity, dosing, immune responses, and limited redosing options.
The financing will support Remedium’s lead programs, expansion of its platform technologies and pipeline, and preparations for first-in-human development.
Cardiometabolic disease is expected to be an early focus area for the company, particularly obesity and type 2 diabetes. Remedium said improving metabolic health earlier and more consistently could provide broader healthspan benefits, given the role of cardiometabolic dysfunction in age-related multimorbidity.
The company’s strategy reflects a broader shift in genetic medicine: using gene therapy not only for rare monogenic diseases, but also as a long-duration delivery system for therapeutic proteins in common chronic conditions.
Remedium remains preclinical. The next key milestones will be whether the platform can achieve sustained therapeutic protein expression, enable predictable dose adjustment, and maintain an acceptable safety profile in human studies.
